RxDoctor Payments Data

Michael Davis, PA

Medical · Encinitas, CANPI 1922115229

Payments from drug & device makers

$3,244in general payments, 2019–2025

Across 142 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$775
  • Boston Scientific$533
  • Nalu Medical, Inc.$226
  • Spinal Simplicity, LLC$195
  • Painteq LLC$185
  • Nevro Corp.$183
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,22399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,244 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$106,239
Medicare patients
391
Services billed
1,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl14$24,502
Buprenorphine30$7,013
Xtampza ErOxycodone Myristate15$6,918
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen192$4,839
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen93$3,866
Fentanyl22$2,338
Gabapentin104$1,418
Oxycodone Hcl91$1,404
Duloxetine Hcl56$801
Morphine Sulfate ErMorphine Sulfate44$792
Naloxone Hcl13$761
Pregabalin38$714
Buprenorphine Hcl13$562
Morphine Sulfate20$542
Hydromorphone Hcl30$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$140$31,42029 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl, Morphine Sulfate$21$8,11763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.

Other medical in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →